NICE recommends natalizumab as a new treatment for adults with highly active relapsing-remitting multiple sclerosis ...

NICE has recommended Tysabri and biosimilar Tyruko as an option for patients with highly active relapsing-remitting multiple ...

NICE has recommended natalizumab for adults with highly active RRMS, citing pregnancy suitability, biosimilar value and NHS ...

NICE has backed NHS use of natalizumab, a key treatment option that is safe for use in pregnancy, for more patients with ...

Please provide your email address to receive an email when new articles are posted on . Individuals enrolled in the open-label extension experienced low discontinuation rates. Those who remained in ...

A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease ...

Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Results from the EVOLVE-MS-1 study show ...

Researchers are continuing to explore how the CXCL13-to-BAFF ratio can be used to advance precision medicine for people with multiple sclerosis.

Depression and anxiety are common among people with multiple sclerosis. This isn't surprising. While multiple sclerosis is unique because it does not affect everyone in the same way, there are some ...

NICE has recommended the drug, natalizumab, as an option for adults with relapsing-remitting MS (RRMS) that remains highly active after a full course of at least one disease-modifying therapy, and for ...